Codiak Makes Executive Appointments
This article was originally published in Scrip
Executive Summary
Codiak BioScienes Inc. has appointed Ariel Jasie chief business officer, Linda Bain chief financial officer (CFO) and Konstantin Konstantinov senior vice president (VP), manufacturing and process sciences. Jasie led the strategy and operations group in the research and early development franchise at Celgene Corporation and previously he was part of the company's business development team. Prior to Celgene he was commercial counsel at Reliant Pharmaceuticals. Bain joins Codiak from Avalanche Biotechnologies, where she was CFO. Previously she was vice president of finance, business operations and treasurer at bluebird bio. She has also been VP of finance, global manufacturing and operations and VP of finance at Genzyme Corporation. Konstantinov was previously responsible for the late-stage bioprocess and technology development at Sanofi's Boston Hub and prior to this he worked at Bayer.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.